Polyamide Compounds for Selective Kappa-Opioid Agonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing κ-opioid receptor (KOR) agonists lack improved activity, druggability, and safety, with issues such as high brain penetration, side effects, and susceptibility to tolerance development.
Innovation Solution
Development of novel amide bond-containing compounds with high KOR receptor affinity, hydrophilicity, and selectivity, along with improved pharmacokinetic and safety profiles, including lower toxicity and fewer side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If KOR agonists are designed to have high affinity for the κ-opioid receptor, then the agonistic potency is improved, but the ability to penetrate the blood brain barrier increases leading to more side effects
Solution Approach 1:
The patent applies local quality by modifying specific regions of the molecule - introducing hydrophilic groups at strategic positions (such as the carboxylic acid group at position 1 and the amide group in the chain) to create localized hydrophilic zones that prevent blood-brain barrier penetration while preserving the core structure's ability to bind to KOR with high affinity
Solution Approach 2:
The patent changes key physicochemical parameters of the KOR agonist molecules, specifically adjusting the hydrophilicity parameter by introducing polar functional groups (carboxylic acid, amide, hydroxyl groups) and controlling the overall charge distribution to achieve high water solubility (greater than 100 µg/mL) while maintaining sub-nanomolar to low nanomolar affinity for KOR
2Object-affected harmful factors
If KOR agonists are developed with improved selectivity for κ-opioid receptor, then the safety profile is improved, but the complexity of molecular design increases
Solution Approach 1:
The patent segments the KOR agonist molecule into distinct functional domains: a basic amine head (providing electrostatic interaction with Asp147), a rigidifying aromatic or cyclic structure (providing π-stacking and hydrophobic interactions), and a flexible linker region containing the amide bond (providing H-bonding capability). This segmentation allows systematic optimization of selectivity by independently tuning each domain's properties
Solution Approach 2:
The patent employs composite molecular structures combining multiple functional groups with complementary properties - the basic amine, aromatic/heteroaromatic ring, amide bond, and carboxylic acid group work synergistically to achieve high KOR selectivity through multiple simultaneous interactions (electrostatic, H-bonding, π-stacking, hydrophobic) with the receptor binding pocket
3Object-affected harmful factors
If KOR agonists are designed to reduce addiction and tolerance, then the safety window is improved, but the pharmacokinetic properties become more difficult to optimize
Solution Approach 1:
The patent applies preliminary anti-action by designing molecules with inherent properties that pre-emptively counteract the development of tolerance and addiction - the high hydrophilicity and charge characteristics are built into the molecular structure from the outset to prevent CNS penetration and reduce the rewarding effects that lead to dependence, while the extended half-life (greater than 4 hours) is engineered to maintain stable therapeutic levels without peaks that trigger tolerance
Data Source
AI summary
The present invention relates to the field of medicines, particularly to synthetic polyamide compounds represented by formula IB, or pharmaceutically acceptable salts and stereoisomers thereof, a composition containing same, a method for preparing same, and use thereof in the field of medicines.